Analysts Conflicted on These Healthcare Names: Clovis Oncology (ZTS) and Zoetis (ZTS)


Analysts have been eager to weigh in on the Healthcare sector with new ratings on Clovis Oncology (NASDAQ: CLVS) and Zoetis (NYSE: ZTS).

Clovis Oncology (NASDAQ: CLVS)

Oppenheimer analyst Leah R. Cann assigned a Hold rating to Clovis Oncology (NASDAQ: CLVS) yesterday. The company’s shares closed yesterday at $47.51, close to its 52-week low of $41.72.

Cann commented:

“Data presented for Rubraca in the treatment of bulky disease support use of Rubraca in this setting. The preclinical data for combination with NKTR-214 were interesting and supportive of further exploration of the combination.”

According to TipRanks.com, Cann is a 5-star analyst with an average return of 20.0% and a 60.2% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.

Clovis Oncology has an analyst consensus of Strong Buy, with a price target consensus of $83.

See today’s analyst top recommended stocks >>

Zoetis (NYSE: ZTS)

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Zoetis (NYSE: ZTS) today and set a price target of $98. The company’s shares closed yesterday at $84.76, close to its 52-week high of $86.38.

Chen wrote:

“We rate ZTS as 12-month price target of $98. Given the company’s durable business model and the positive outlook for macro factors, we think the multiple will hold and upwards earnings revisions should drive shares higher. Valuation Summary We use a blend of DCF and multiples analysis (EV/EBITDA) to get to our 12- month price target of $98.”

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -5.4% and a 38.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.

Zoetis has an analyst consensus of Moderate Buy, with a price target consensus of $91.71.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts